We use cookies to understand how you use our site and to improve your experience. This includes personalizing content and advertising. To learn more, click here. By continuing to use our site, you accept our use of cookies. Cookie Policy.

Features Partner Sites Information LinkXpress hp
Sign In
Advertise with Us

Download Mobile App




PSA Assays Added to Tumor Marker Portfolio

By LabMedica International staff writers
Posted on 16 Dec 2008
A comprehensive tumor marker portfolio has added total prostate-specific antigen (PSA) assay and free PSA assays to its menu.

Prostate cancer is the second leading cause of cancer death in men. More...
Therefore, it is recommended that all men 50 or older be screened for prostate cancer by having an annual PSA test. If detected in its early stages, the 5-year survival rate for prostate cancer is nearly 100%.

Roche Diagnostics (Basel, Switzerland) has introduced the Elecsys total PSA and Elecsys free PSA assays to its immunoassay tumor marker menu for use on the Roche cobas 6000 analyzer series.

The advantages of the Roche Elecsys total and free PSA assays include better precision, an 18-minute turnaround time, and a convenient 20-μL-sample size for both assays. The tumor marker portfolio has a menu that already includes alpha fetal protein (AFP), carcinoembryonic antigen (CEA), cancer antigen (CA) 19-9 (mainly used for pancreatic cancer), CA 15-3 (for monitoring breast cancer) and CA 125 (for ovarian cancer). Currently these assays are also available for use on the Roche Elecsys 2010 system and the Modular Analytics E 170 module.

Roche Diagnostics offers a broad portfolio of diagnostics tools that test for congestive heart failure, human immunodeficiency virus (HIV), Hepatitis B and C, fertility testing, diabetes, and many other diseases. This wide array of testing products and services is supplied to physicians, patients, hospitals, and laboratories.

Related Links:
Roche Diagnostics


Gold Member
Collection and Transport System
PurSafe Plus®
POC Helicobacter Pylori Test Kit
Hepy Urease Test
Autoimmune Liver Diseases Assay
Microblot-Array Liver Profile Kit
Gold Member
Hematology Analyzer
Medonic M32B
Read the full article by registering today, it's FREE! It's Free!
Register now for FREE to LabMedica.com and get access to news and events that shape the world of Clinical Laboratory Medicine.
  • Free digital version edition of LabMedica International sent by email on regular basis
  • Free print version of LabMedica International magazine (available only outside USA and Canada).
  • Free and unlimited access to back issues of LabMedica International in digital format
  • Free LabMedica International Newsletter sent every week containing the latest news
  • Free breaking news sent via email
  • Free access to Events Calendar
  • Free access to LinkXpress new product services
  • REGISTRATION IS FREE AND EASY!
Click here to Register








Channels

Immunology

view channel
Image: Whole-genome sequencing enables broader detection of DNA repair defects to guide PARP inhibitor cancer therapy (Photo courtesy of Illumina)

Whole-Genome Sequencing Approach Identifies Cancer Patients Benefitting From PARP-Inhibitor Treatment

Targeted cancer therapies such as PARP inhibitors can be highly effective, but only for patients whose tumors carry specific DNA repair defects. Identifying these patients accurately remains challenging,... Read more

Pathology

view channel
Image: AI models combined with DOCI can classify thyroid cancer subtypes (Photo courtesy of T. Vasse et al., doi 10.1117/1.BIOS.3.1.015001)

AI-Powered Label-Free Optical Imaging Accurately Identifies Thyroid Cancer During Surgery

Thyroid cancer is the most common endocrine cancer, and its rising detection rates have increased the number of patients undergoing surgery. During tumor removal, surgeons often face uncertainty in distinguishing... Read more
Copyright © 2000-2026 Globetech Media. All rights reserved.